BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. Clin Mol Hepatol 2015;21:49-59. [PMID: 25834802 DOI: 10.3350/cmh.2015.21.1.49] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Wadhwa K, Pahwa R, Kumar M, Kumar S, Sharma PC, Singh G, Verma R, Mittal V, Singh I, Kaushik D, Jeandet P. Mechanistic Insights into the Pharmacological Significance of Silymarin. Molecules 2022;27:5327. [PMID: 36014565 DOI: 10.3390/molecules27165327] [Reference Citation Analysis]
2 Koltai T, Fliegel L. Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. J Evid Based Integr Med 2022;27:2515690X211068826. [PMID: 35018864 DOI: 10.1177/2515690X211068826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Blidisel A, Marcovici I, Coricovac D, Hut F, Dehelean CA, Cretu OM. Experimental Models of Hepatocellular Carcinoma-A Preclinical Perspective. Cancers (Basel) 2021;13:3651. [PMID: 34359553 DOI: 10.3390/cancers13153651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
4 Antal DS, Ardelean F, Avram S, Pavel IZ, Danciu C, Soica C, Dehelean C. Flavonolignans: One Step Further in the Broad-Spectrum Approach of Cancer. Anticancer Agents Med Chem 2020;20:1817-30. [PMID: 31976848 DOI: 10.2174/1871520620666200124112649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tighe SP, Akhtar D, Iqbal U, Ahmed A. Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review. J Clin Transl Hepatol 2020;8:454-8. [PMID: 33447529 DOI: 10.14218/JCTH.2020.00012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
6 Murali Iyangar R, Devaraj E. Silibinin Triggers the Mitochondrial Pathway of Apoptosis in Human Oral Squamous Carcinoma Cells. Asian Pac J Cancer Prev 2020;21:1877-82. [PMID: 32711410 DOI: 10.31557/APJCP.2020.21.7.1877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
7 Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol 2020;12:1758835920927602. [PMID: 32518599 DOI: 10.1177/1758835920927602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
8 Kiruthiga C, Devi KP, Nabavi SM, Bishayee A. Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E562. [PMID: 32121322 DOI: 10.3390/cancers12030562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 10.5] [Reference Citation Analysis]
9 Asgari V, Landarani-isfahani A, Salehi H, Amirpour N, Hashemibeni B, Rezaei S, Bahramian H. The Story of Nanoparticles in Differentiation of Stem Cells into Neural Cells. Neurochem Res 2019;44:2695-707. [DOI: 10.1007/s11064-019-02900-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 An W, Lai H, Zhang Y, Liu M, Lin X, Cao S. Apoptotic Pathway as the Therapeutic Target for Anticancer Traditional Chinese Medicines. Front Pharmacol 2019;10:758. [PMID: 31354479 DOI: 10.3389/fphar.2019.00758] [Cited by in Crossref: 18] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
11 Yoo JJ, Yu SJ, Na J, Kim K, Cho YY, Lee YB, Cho EJ, Lee JH, Kim YJ, Youn H, Yoon JH. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E1292. [PMID: 30875800 DOI: 10.3390/ijms20061292] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
12 Xiong DD, Dang YW, Lin P, Wen DY, He RQ, Luo DZ, Feng ZB, Chen G. A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma. J Transl Med 2018;16:220. [PMID: 30092792 DOI: 10.1186/s12967-018-1593-5] [Cited by in Crossref: 98] [Cited by in F6Publishing: 142] [Article Influence: 24.5] [Reference Citation Analysis]
13 Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res 2018;32:2202-13. [PMID: 30080294 DOI: 10.1002/ptr.6171] [Cited by in Crossref: 121] [Cited by in F6Publishing: 147] [Article Influence: 30.3] [Reference Citation Analysis]
14 Mao J, Yang H, Cui T, Pan P, Kabir N, Chen D, Ma J, Chen X, Chen Y, Yang Y. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. Eur J Pharmacol 2018;832:39-49. [PMID: 29782854 DOI: 10.1016/j.ejphar.2018.05.027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
15 Prieto-Domínguez N, Méndez-Blanco C, Carbajo-Pescador S, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy. Oncotarget 2017;8:91402-14. [PMID: 29207653 DOI: 10.18632/oncotarget.20592] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 8.6] [Reference Citation Analysis]
16 Bosch-barrera J, Queralt B, Menendez JA. Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treatment Reviews 2017;58:61-9. [DOI: 10.1016/j.ctrv.2017.06.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
17 Morsi NG, Ali SM, Elsonbaty SS, Afifi AA, Hamad MA, Gao H, Elsabahy M. Poly(glycerol methacrylate)-based degradable nanoparticles for delivery of small interfering RNA. Pharm Dev Technol 2018;23:387-99. [PMID: 28347210 DOI: 10.1080/10837450.2017.1312443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ezhilarasan D, Evraerts J, Sid B, Calderon PB, Karthikeyan S, Sokal E, Najimi M. Silibinin induces hepatic stellate cell cycle arrest via enhancing p53/p27 and inhibiting Akt downstream signaling protein expression. Hepatobiliary & Pancreatic Diseases International 2017;16:80-7. [DOI: 10.1016/s1499-3872(16)60166-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
19 Cho Y, Lee YB, Lee JH, Lee DH, Cho EJ, Yu SJ, Kim YJ, Kim JI, Im JH, Lee JH, Oh EJ, Yoon JH. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. PLoS One 2016;11:e0160822. [PMID: 27494117 DOI: 10.1371/journal.pone.0160822] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
20 Zhu XX, Ding YH, Wu Y, Qian LY, Zou H, He Q. Silibinin: a potential old drug for cancer therapy. Expert Rev Clin Pharmacol. 2016; 18: 1-8 Epub ahead of print. [PMID: 27362364 DOI: 10.1080/17512433.2016.1208563] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
21 Liao CY, Lee CC, Tsai CC, Hsueh CW, Wang CC, Chen IH, Tsai MK, Liu MY, Hsieh AT, Su KJ. Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma. Biomed Res Int. 2015;2015:840542. [PMID: 26858957 DOI: 10.1155/2015/840542] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]